Calamos S&P 500 Structured Alt Protection ETF - March CPSR
26.36 USD +0.05 (+0.17%)
Nov 12, 2026, 2:33 PM EST
26.35 Day range 26.35
24.80 52-week range 26.33
- YTD
- +4.64%
- 1 year
- +5.65%
News
benzinga.com Calamos' New ETFs Promise Market Exposure Without The Meltdowns Calamos added 2 new Structured Protection ETFs in April, providing exposure to S&P 500 and Russell 2000 with downside protection and capped gains.
benzinga.com Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has- benzinga.com 48 Biggest Movers From Yesterday Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT performance drink in Walmart…
benzinga.com 30 Stocks Moving In Tuesday's Mid-Day Session Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's morning trading, 87 companies set new 52-week lows.
benzinga.com 45 Stocks Moving In Monday's Mid-Day Session Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
benzinga.com PureTech Founded Entity Gelesis Receives $30M Plenity Order From Ro PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Gelesis, Inc.
benzinga.com Capstar Special Purpose Acquisition Corp. Reports Terms Of Deal With Gelesis Revised To Imply Equity Value Of $675M, Down From $900M Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) (“Capstar”), a special purpose acquisition company, announced that the valuation of its previously announced transaction with Gelesis, Inc.- benzinga.com Capstar Special Purpose Acquisition Merging Partner Gelesis Announces Nature's Scientific Reports Features Gelesis' Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage New paper describes the first superabsorbent hydrogel technology made from naturally derived building blocks designed to address obesity and gut related conditions by emulating compositional and…
benzinga.com FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's morning session, 92 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's session saw 466 companies set new 52-week highs.